Add to ORKGThe kidneys are one of the main dose-limiting organs in peptide receptor radionuclide ther-apy and due to large inter-individual variations in renal toxicity, biomarkers are urgently needed in order to optimize therapy and reduce renal tissue damage. The aim of this study was to investigate the transcriptional, functional, and morphological effects on renal tissue after 177Lu-octreotate administration in normal mice, and to identify biomarkers for radiation induced renal toxicity
Contains fulltext : 89433.pdf (publisher's version ) (Closed access)Peptide-recept...
Purpose: Peptide receptor radionuclide therapy (PRRT) of neuroendocrine tumours with 90Y-DOTATOC and...
Background/Aims: Peptide receptor radionuclide therapy (PRRT) is becoming clinical routine for manag...
Patients suffering from neuroendocrine tumors are oftentimes presented with spread disease at the ti...
C57BL/6N mice were i.v. injected with 0, 30, 60, 90, 120, or 150 MBq 177Lu-octreotate (0, 16, 29, 40...
AbstractIntroductionThe kidneys are one of the main dose limiting organs in 177Lu-octreotate therapy...
Purpose: The purpose of this project was to investigate gene regulation of a predetermined panel of ...
Contains fulltext : 89547.pdf (publisher's version ) (Closed access)We determined ...
Aims: Peptide receptor radionuclide therapy (PRRT) is in clinical use today to treat metastatic neur...
Purpose Peptide receptor radionuclide therapy (PRRT) has become an important treatment option in the...
Targeted radionuclide therapy with 177Lu-DOTATATE for patients with neuroendocrine tumours utilises ...
We determined the renal radiation dose of a series of 111In-labeled peptides using animal SPECT. Bec...
Contains fulltext : 51440.pdf (publisher's version ) (Closed access)Nephrotoxicity...
Background: The kidneys are regarded as one of the main dose-limiting organs in the treatment of neu...
Folate receptor (FR)-targeted radionuclide therapy using folate radioconjugates is of interest due t...
Contains fulltext : 89433.pdf (publisher's version ) (Closed access)Peptide-recept...
Purpose: Peptide receptor radionuclide therapy (PRRT) of neuroendocrine tumours with 90Y-DOTATOC and...
Background/Aims: Peptide receptor radionuclide therapy (PRRT) is becoming clinical routine for manag...
Patients suffering from neuroendocrine tumors are oftentimes presented with spread disease at the ti...
C57BL/6N mice were i.v. injected with 0, 30, 60, 90, 120, or 150 MBq 177Lu-octreotate (0, 16, 29, 40...
AbstractIntroductionThe kidneys are one of the main dose limiting organs in 177Lu-octreotate therapy...
Purpose: The purpose of this project was to investigate gene regulation of a predetermined panel of ...
Contains fulltext : 89547.pdf (publisher's version ) (Closed access)We determined ...
Aims: Peptide receptor radionuclide therapy (PRRT) is in clinical use today to treat metastatic neur...
Purpose Peptide receptor radionuclide therapy (PRRT) has become an important treatment option in the...
Targeted radionuclide therapy with 177Lu-DOTATATE for patients with neuroendocrine tumours utilises ...
We determined the renal radiation dose of a series of 111In-labeled peptides using animal SPECT. Bec...
Contains fulltext : 51440.pdf (publisher's version ) (Closed access)Nephrotoxicity...
Background: The kidneys are regarded as one of the main dose-limiting organs in the treatment of neu...
Folate receptor (FR)-targeted radionuclide therapy using folate radioconjugates is of interest due t...
Contains fulltext : 89433.pdf (publisher's version ) (Closed access)Peptide-recept...
Purpose: Peptide receptor radionuclide therapy (PRRT) of neuroendocrine tumours with 90Y-DOTATOC and...
Background/Aims: Peptide receptor radionuclide therapy (PRRT) is becoming clinical routine for manag...